Serina Therapeutics CSO sells shares after option exercises

Serina Therapeutics, Inc. reported insider stock transactions by its Chief Scientific Officer on a Form 4.

Rhea-AI Filing Summary

Serina Therapeutics, Inc. reported insider stock transactions by its Chief Scientific Officer on a Form 4. On December 9, 2025, the officer exercised stock options to buy 600 shares of common stock at an exercise price of $0.06 per share, then sold 600 shares at a weighted average price of $3.3133 per share, with individual sale prices ranging from $3.31 to $3.315. On December 10, 2025, the officer similarly exercised options for 645 shares at $0.06 per share and sold 645 shares at $3.35 per share.

The filing shows these transactions as direct ownership and notes that the related stock options, which carry an exercise price of $0.06 and expire on May 6, 2031, are fully vested. After the reported option exercises, the officer holds 370,441 stock options with the same exercise price.

Insider Trade Summary

Exercise and Sale: 1,245 shares ($4K approx. pre-tax spread)

Exercise and Sale 6 txns

Insider Moreadith Randall

Role Chief Scientific Officer

Sold 1,245 shs ($4K)

Approx. gross sale proceeds $4K

Approx. exercise cost $74.70

Approx. pre-tax spread $4K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	645	$0.00	$0.00
Grant/Award	Common Stock	645	$0.06	$38.70
Sale	Common Stock	645	$3.35	$2K
Exercise	Stock Option (right to buy)	600	$0.00	$0.00
Exercise	Common Stock	600	$0.06	$36.00
Sale	Common Stock	600	$3.3133	$2K

Holdings After Transaction: Stock Option (right to buy) — 370,441 contracts (Direct); Common Stock — 0 shares (Direct)

Footnotes (2)

1. F1. The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.31 to $3.315. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
2. F2. The stock options are fully vested.

FAQ

What insider transactions did Serina Therapeutics (SER) report on this Form 4?

The Chief Scientific Officer exercised stock options at $0.06 per share and sold the resulting common shares on December 9 and 10, 2025 at market prices above $3 per share.

How many Serina Therapeutics (SER) shares did the officer buy and sell?

The officer acquired 600 shares on December 9, 2025 and 645 shares on December 10, 2025 through option exercises, then sold 600 shares and 645 shares of common stock on those same dates.

What prices were involved in the Serina Therapeutics (SER) insider stock sales?

Shares sold on December 9, 2025 had a weighted average sale price of $3.3133 per share, with individual trades between $3.31 and $3.315, while shares sold on December 10, 2025 were sold at $3.35 per share.

What is the exercise price and expiration date of the Serina Therapeutics (SER) stock options?

The stock options reported have an exercise price of $0.06 per share and an expiration date of May 6, 2031.

How many Serina Therapeutics (SER) stock options does the officer hold after these transactions?

After the reported exercises, the officer holds 370,441 stock options with an exercise price of $0.06 per share.

Is the reporting person an officer or director at Serina Therapeutics (SER)?

Yes. The reporting person is identified as an Officer, serving as Chief Scientific Officer of Serina Therapeutics, Inc.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/11/2025 - 04:11 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Moreadith Randall

(Last) (First) (Middle)

601 GENOME WAY, SUITE 2001

(Street)

HUNTSVILLE AL 35806

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Serina Therapeutics, Inc. [ SER ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/09/2025		M		600	A	$0.06	600	D
Common Stock	12/09/2025		S		600	D	$3.3133(1)	0	D
Common Stock	12/10/2025		A		645	A	$0.06	645	D
Common Stock	12/10/2025		S		645	D	$3.35	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.06	12/09/2025		M			600	(2)	05/06/2031	Common Stock	600	$0	371,086	D
Stock Option (right to buy)	$0.06	12/10/2025		M			645	(2)	05/06/2031	Common Stock	645	$0	370,441	D

Explanation of Responses:

1. The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.31 to $3.315. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

2. The stock options are fully vested.

Remarks:

	/s/ Randall Moreadith	12/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.